Generated by AI
NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division. Its current commercial portfolio includes Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with these therapies used alongside standard cancer treatments in approved markets. The company operates across the United States, Europe, Japan, Greater China, and other international regions, supporting patients through portable device-based treatment systems and related services. NovoCure Ltd. plays a specialized role in the cancer care market by offering a device-led treatment platform for difficult-to-treat solid tumors, combining medical technology, clinical support, and oncology-focused commercialization.
WebsiteNeuhofstrasse 21
Baar, 6340
Switzerland
The latest articles about NVCR.
Summary of Nov 9's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Tipranks Press Release.
Summary of Jun 7's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about NVCR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.